What is Sermorelin?

Sermorelin is GHRH(1-29), the shortest N-terminal fragment of growth hormone-releasing hormone that retains GH-releasing activity. It stimulates pituitary GHRH receptors rather than acting through the ghrelin receptor. [14][3]

The 1-29 length matters because the active N-terminal portion of GHRH is enough to stimulate pituitary GH release when somatotroph cells can respond. It is shorter than native GHRH and more route-sensitive than long-acting GHRH analogs. [14][3][29]

Modern use language often places Sermorelin in adult GH-axis support and anti-aging-style contexts, while its core pharmacologic identity remains a pituitary GHRH-receptor signal rather than direct growth hormone replacement. [30][3][24]

What Sermorelin is investigated for

Sermorelin evidence is grouped by practical use case and injectable and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

GH-axis stimulation

Injectable, Intranasal

66% Moderate

GH-axis stimulation is biologically grounded, but interpretation depends on route, pituitary function, and the population being studied. [14][30]

Human evidence

Human studies support GH response in diagnostic and GH-deficiency contexts. [14][30]

Animal / mechanistic evidence

GHRH(1-29) directly stimulates the pituitary GHRH receptor when somatotroph function is intact. [14][30]

Adult lean-mass and anti-aging support

Injectable

24% Limited

Adult lean-mass, fat-loss, and anti-aging claims should remain cautious, monitored, and distinct from historical GH-deficiency contexts. [4][24]

Human evidence

Adult wellness, lean-mass, fat-loss, and anti-aging outcomes have not been established with large controlled trials. [4][24]

Animal / mechanistic evidence

GHRH physiology supports the idea of upstream GH stimulation. [4][24]

Sleep quality

Injectable

16% Insufficient

Sleep-quality positioning should remain an indirect GH-axis hypothesis, not a demonstrated sermorelin outcome. [4][24]

Human evidence

Dedicated controlled sermorelin sleep-quality endpoint trials are not established. [4][24]

Animal / mechanistic evidence

The sleep rationale is indirect, based on GHRH physiology, nocturnal GH-pulse timing, and adult GH-secretagogue review literature. [14][4]

Anti-aging support

Injectable

12% Insufficient

Anti-aging support is a common reader intent, but it should remain an insufficient-evidence claim separate from GH-axis stimulation. [4][24]

Human evidence

Sermorelin has not shown controlled longevity, healthspan, frailty, or age-reversal outcomes in the cited literature. [4][24]

Animal / mechanistic evidence

The anti-aging rationale is indirect, based on GHRH and GH-axis physiology rather than direct aging biology. [4]

Evidence snapshot

Overall confidence

Moderate

66%

Sermorelin has real GH-response and historical product evidence. Current adult wellness claims sit outside the best-supported pediatric, diagnostic, and GH-deficiency contexts. [31][30]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

66%

Human evidence

Moderate

GH-response studies, diagnostic use, and pediatric GH-deficiency history support a real human evidence base. Broad adult anti-aging outcomes remain unestablished. [14][30][3]

30%

Animal / preclinical

Limited

Preclinical and route-degradation work mainly supports pharmacology and formulation questions. It is not the main confidence driver for sermorelin. [29][1]

65%

Mechanism support

Moderate

GHRH(1-29) receptor activity provides a clear upstream GH-release mechanism when pituitary function is intact. [14][3]

Forms & administration

Sermorelin administration is route-specific. Modern compounded protocols usually use subcutaneous injection, while intranasal research is older and not directly interchangeable. [31][30][13]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common injectable protocols use 0.2-0.5 mg once daily. [30][31]

Frequency

Once-daily dosing is the common app pattern for injectable sermorelin. [30]

Timing Considerations

Before-bed timing aligns with GH-pulse scheduling and makes fasting easier to standardize. [14]

Cycle Length

Common adult protocols use 3-6 month reassessment windows for IGF-1, glucose, waist, sleep, and recovery notes. [4][24]

What to expect

Weeks 2-4

Bedtime injectable use may first show changes in sleep quality, morning energy, appetite, or water retention. [4]

Weeks 8-12

IGF-1, fasting glucose, waist, recovery notes, and training tolerance become clearer once bedtime timing is consistent. [24]

3-6 months

Longer cycles show whether GH-axis markers, waist, sleep, and recovery patterns remain aligned with the original goal. [4][30]

After stopping

Sleep, appetite, water retention, and IGF-1-related markers may drift toward baseline after GH-axis stimulation ends. [4][30]

Safety profile

Injectable sermorelin safety centers on injection-site tolerance, flushing or headache, water retention, glucose and IGF-1 effects, pregnancy avoidance, active malignancy caution, and sports prohibition. [31][30]

Common side effects

Injection-site pain or swelling [33]
Flushing [3]
Headache [3]
Water retention [24]

Cautions

Glucose monitoring [31][30]
Active malignancy [31][30]
Sports prohibited [34]

Who Sermorelin is not for

Route-specific avoid and medical-review notes:

Active or recent cancer
Avoid outside specialist-directed care because GH/IGF-1 pathway stimulation can be inappropriate in malignancy contexts. [31][30]
Pregnancy or breastfeeding
Avoid because reproductive and lactation safety are not established for unapproved GH secretagogue use. [31][30]
Acromegaly or GH excess
Do not add GH secretagogue stimulation when GH/IGF-1 excess is present or suspected. [31][30]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Diabetes medications
Diabetes medications can become harder to adjust when injectable GH-axis stimulation shifts glucose control; this is a theoretical GH/insulin-axis caution. [31][30]
Other GH-axis agents
GHRH analogs, GHRPs, or HGH can add overlapping IGF-1, water-retention, glucose, and sports-risk concerns with injectable sermorelin; this is a stack-level safety caution. [31][30]

Regulatory status

United States

Geref (sermorelin acetate) is a discontinued FDA product, not a currently marketed FDA-approved sermorelin option. FDA data note discontinuation was not for safety or effectiveness reasons, but compounded injectable or intranasal sermorelin remains separate from FDA approval. [31][33]

Route	FDA drug approval	503A compounding
Injectable	Not Listed As of 2026-06-21, Geref (sermorelin acetate) appeared in FDA data as a discontinued product, with a note that discontinuation was not for safety or effectiveness reasons. That is not a currently marketed FDA-approved option for injectable or intranasal sermorelin. [31]	Not Listed Geref's discontinued FDA status does not authorize current compounded injectable or intranasal sermorelin. Compounded preparations are not FDA-approved drugs. [31][33]
Intranasal	Not Listed As of 2026-06-21, Geref (sermorelin acetate) appeared in FDA data as a discontinued product, with a note that discontinuation was not for safety or effectiveness reasons. That is not a currently marketed FDA-approved option for injectable or intranasal sermorelin. [31]	Not Listed Geref's discontinued FDA status does not authorize current compounded injectable or intranasal sermorelin. Compounded preparations are not FDA-approved drugs. [31][33]

Injectable

FDA drug approval

Not Listed

As of 2026-06-21, Geref (sermorelin acetate) appeared in FDA data as a discontinued product, with a note that discontinuation was not for safety or effectiveness reasons. That is not a currently marketed FDA-approved option for injectable or intranasal sermorelin. [31]

503A compounding

Not Listed

Geref's discontinued FDA status does not authorize current compounded injectable or intranasal sermorelin. Compounded preparations are not FDA-approved drugs. [31][33]

Intranasal

FDA drug approval

Not Listed

503A compounding

Not Listed

Geref's discontinued FDA status does not authorize current compounded injectable or intranasal sermorelin. Compounded preparations are not FDA-approved drugs. [31][33]

International

EU/Europe, UK, Canada, and Australia should be checked by local medicine and compounding rules; historical U.S. product status does not establish current approval elsewhere.

Sports & competition

WADA's 2026 Prohibited List treats GHRH analogs such as sermorelin as S2-prohibited; tested athletes should treat injectable or intranasal use as prohibited without a valid TUE. [34]

How it works

Sermorelin is GHRH(1-29), the N-terminal fragment that stimulates pituitary GHRH receptors. It acts through the GHRH pathway rather than the ghrelin/GHS receptor pathway used by GHRP-2, GHRP-6, or ipamorelin, so its food timing and stack logic are different. [14][3]

The mechanism requires responsive somatotroph cells, the GH-producing cells in the pituitary. That makes sermorelin a test or stimulation signal, not the same as exogenous GH replacement in severe pituitary failure. Route and formulation matter because short peptide degradation can limit exposure. [3][29][1]

Research gaps & open questions

What the current literature has not yet settled about Sermorelin:

Adult wellness outcomes need controlled trials with body composition, sleep, function, glucose, and IGF-1 endpoints. [4][24]

Compounded-product equivalence to historical Geref should not be assumed without quality and formulation evidence. [31][33]

Pituitary function, age, baseline IGF-1, and somatostatin tone likely affect response and need better practical stratification. [14]

Common questions

Is sermorelin currently FDA-approved?

No current marketed FDA-approved sermorelin option is listed. Geref was a discontinued sermorelin acetate product, and compounded versions are separate from FDA approval. [31][33]

How is sermorelin different from GHRPs?

Sermorelin is a GHRH fragment that stimulates pituitary GHRH receptors; GHRP-class peptides act through ghrelin/GHS receptor signaling. [14][3]

Is sermorelin banned in tested sports?

Yes. WADA treats GHRH analogs such as sermorelin as S2-prohibited without a valid TUE. [34]

Myths & misconceptions

Myth

Sermorelin is currently sold as an FDA-approved product.

Reality

The historical Geref product is listed as discontinued; compounded products are not the same as a currently marketed FDA-approved product. [31][33]

Myth

Sermorelin works just like injected HGH.

Reality

Sermorelin stimulates upstream pituitary release; it requires responsive pituitary cells and is not equivalent to exogenous GH replacement. [14]

History & discovery

Sermorelin's history sits between classic pediatric endocrinology and modern compounded GH-axis use: it is a GHRH(1-29) analog that once had a marketed FDA-approved product, Geref. [31][3]

Early studies used GRF(1-29) and somatomedin C/IGF-1 measurements to evaluate growth hormone deficiency and pituitary responsiveness. [14]

Once-daily subcutaneous GHRH therapy was studied in children with growth hormone deficiency, establishing the clinical context behind Geref. [30]

Current FDA records list Geref as discontinued and not withdrawn for safety or effectiveness, which separates historical approval from today's compounded-market use. [31]

Published research 34 studies

[1]

Interactions of GRF(1-29)NH2 with plasma proteins and their effects on the release of the peptide from a PLAGA matrix.

Journal of controlled release : official journal of the Controlled Release Society, 2005 Sep 2. review.

[2]

Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).

Bioconjugate chemistry, 2007 Mar-Apr. review.

[3]

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999 Aug. review.

[4]

Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

Clinical interventions in aging, 2006. review.

[5]

A comparison of the biological activities of authentic rat GRF(1-43)OH with the analogue rat GRF(1-29)NH2.

Canadian journal of physiology and pharmacology, 1991 Feb. animal.

[6]

An analogue of growth hormone releasing factor (GRF), (Ac-Try1, D-Phe2)-GRF-(1-29), specifically antagonizes the facilitation of the flexor reflex induced by intrathecal vasoactive intestinal peptide in rat spinal cord.

Neuropeptides, 1991 Mar. animal.

[7]

Effects of GRF (1-29) NH2 on short-term memory: neuroendocrine and neuropsychological assessment in healthy young subjects.

Methods and findings in experimental and clinical pharmacology, 1990 Sep. human clinical.

[8]

VIP antagonist [N-Ac-Tyr1,D-Phe2]-GRF-(1-29)-NH2: an inhibitor of vasodilation in the feline colon.

The American journal of physiology, 1990 Aug. review.

[9]

Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.

Endocrinology, 1985 Jun. animal.

[10]

Does growth hormone releasing factor desensitize the somatotroph? Interpretation of responses of growth hormone during and after 10-hour infusion of GRF 1-29 amide in man.

Clinical endocrinology, 1986 Feb. in vitro.

[11]

Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29.

Clinical endocrinology, 1986 Mar. human clinical.

[12]

Lack of effect of muscarinic cholinergic blockade on the GH responses to GRF 1-29 and TRH in acromegalic subjects.

Clinical endocrinology, 1986 Apr. human clinical.

[13]

The effects of intranasal insufflation of growth hormone releasing factor analogue GRF 1-29 NH2 on growth hormone secretion in children with short stature.

Acta endocrinologica. Supplementum, 1986. review.

[14]

Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency.

European journal of pediatrics, 1986 Dec. review.

[15]

[Response of growth hormone to GRF(1-29)NH2 in 12 cases of active acromegaly].

Revista clinica espanola, 1987 Mar. review.

[16]

Applications of BOP reagent in solid phase synthesis. Advantages of BOP reagent for difficult couplings exemplified by a synthesis of [Ala 15]-GRF(1-29)-NH2.

International journal of peptide and protein research, 1988 Jan. review.

[17]

GH response to GRF (1-29) NH2 in female rats treated neonatally with estradiol benzoate or testosterone propionate.

Journal of steroid biochemistry, 1988 Jun. animal.

[18]

The synthetic peptide GRF (1-29)-NH2 with growth hormone releasing activity penetrates human epidermis in nitro.

Acta pharmaceutica Suecica, 1988. review.

[19]

Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes.

Endocrinology, 1985 Nov. animal.

[20]

Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine.

Clinical endocrinology, 1986 Jun. review.

[21]

[Effects of GRF 1-29 in normal and hypotrophic lambs].

Reproduction, nutrition, developpement, 1988. review.

[22]

Secondary structure of the human growth hormone releasing factor (GRF 1-29) by two-dimensional 1H-nmr spectroscopy.

Biopolymers, 1988 Dec. review.

[23]

[Influence of twice-daily injections of GRF 1-29 on production, feed intake and nutritional status of lactating goats].

Reproduction, nutrition, developpement, 1988. review.

[24]

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

Translational andrology and urology, 2020 Mar. review.

[25]

A potentially effective drug for patients with recurrent glioma: sermorelin.

Annals of translational medicine, 2021 Mar. review.

[26]

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026 Jan 1. review.

[27]

Study of the activation mechanism of human GRF(1-29)NH2 on rat mast cell histamine release.

Inflammation research : official journal of the European Histamine Research Society ... [et al.], 1995 Feb. in vitro.

[28]

Histamine release on rat pleural and peritoneal mast cells elicited by human GRF(1-29)NH2.

International archives of allergy and immunology, 1993. in vitro.

[29]

The involvement of dipeptidyl peptidase IV in brush-border degradation of GRF(1-29)NH2 by intestinal mucosal cells.

The Journal of pharmacy and pharmacology, 1995 Aug. in vitro.

[30]

Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.

The Journal of clinical endocrinology and metabolism, 1996 Mar. human clinical.

[31]

Drugs@FDA/openFDA query for sermorelin acetate / Geref

U.S. Food and Drug Administration / openFDA. database query.

[32]

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act

U.S. Food and Drug Administration, 2026-05-14. regulatory.

[33]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[34]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency, 2026. regulatory.